Semaglutide reduces Cardiovascular Events Among Patients with Variable CV Risk: A Combined Post-hoc analysis of the SUSTAIN 6 and PIONEER trials (https://doi.org/10.1111/dom.13955)

Cardiovascular outcome trials have been completed with semaglutide using the s.c (SUSTAIN 6) and oral (PIONEER) formulations. This post-hoc analysis combined the data from both trials to investigate the occurrence of MACE (major adverse cardiovascular events) events and hospitalization for heart failure according to baseline CV risk, i.e the presence or absence of prior CV disease and/or CKD; prior MI or stroke; or prior evidence of heart failure. Husain et al showed that the hazard ratios for MACE were <1.0 in all subgroups, except those with prior heart failure. Thus, the cardiovascular risk lowering benefits of semaglutide seem to apply to a broad patient population with varying levels of baseline CV risk.